Brief: Supernus Pharmaceuticals Says Co, Newron Received Notice Letters From MSN, Optimus & Zenara
19/05/2021 21:31
May 19 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* SUPERNUS PHARMACEUTICALS - ON EACH OF MAY 14, MAY 15, &
MAY 17,
2021, CO, NEWRON RECEIVED NOTICE LETTERS FROM MSN, OPTIMUS &
ZENARA, RESPECTIVELY
* SUPERNUS PHARMACEUTICALS - NOTICE LETTERS ADVISED CO,
NEWRON OF
ANDAS BY MSN, OPTIMUS, ZENARA TO FDA SEEKING APPROVAL FOR
SAFINAMIDE MESYLATE TABLETS
* SUPERNUS PHARMACEUTICALS - NOTICE LETTERS DIRECTED TO
THREE
XADAGO PATENTS THAT EXPIRE BETWEEN JUNE 2027 AND DECEMBER 2028
* SUPERNUS PHARMACEUTICALS - CURRENTLY REVIEWING DETAILS OF
NOTICE
LETTERS WITH ITS PARTNERS
Source: (https://bit.ly/3wjlbki)
Further company coverage: NWRN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study